SEC Form 4 · accession 0001179110-16-018851
Editas Medicine, Inc. · EDIT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexis Borisy
Director
Period of report
Feb 8, 2016
Accepted (ET)
Feb 9, 2016 · 5:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001650664
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Feb 8, 2016 | C | 0 | — | A | 0 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A-1 Preferred StockF4,F3,F2,F5 | — | Feb 8, 2016 | C | 0 | D | — | — | Common Stock | 0 | 0 | I |
| Series A-2 Preferred StockF4,F3,F2,F5 | — | Feb 8, 2016 | C | 0 | D | — | — | Common Stock | 0 | 0 | I |
| Series B Preferred StockF4,F3,F2,F5 | — | Feb 8, 2016 | C | 0 | D | — | — | Common Stock | 0 | 0 | I |
Explanation of responses
- F1Represents 4,656,176 shares held by Third Rock Ventures III, L.P. (the "Fund") received by the Fund upon conversion of Series A-1, Series A-2 and Series B Preferred Stock upon closing of the Issuer's initial public offering.
- F2The Series A-1, Series A-2 and Series B Preferred Stock converted into Common Stock on a 2.6-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1, Series A-2 and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- F3The reporting person is a partner of Third Rock Ventures GP III, L.P., which is the general partner of the Fund. The reporting person disclaims beneficial ownership over the shares held by the Fund, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
- F4Prior to the conversion, the Fund held 6,628,542 shares of Series A-1 Preferred Stock, 5,255,300 shares of Series A-2 Preferred Stock and 222,222 shares of Series B Preferred Stock.
- F5Prior to the conversion, the shares of Common Stock underlying Series A-1, Series A-2 and Series B Preferred Stock held by the Fund were 2,549,437, 2,021,269 and 85,470, respectively.